What is claimed is:

1. A compound according to formula (I) hereinbelow:

or a pharmaceutically acceptable salt thereof.



I

wherein:

R1 is selected from the group consisting of H, CN, and halogen;

R2 is selected from the group consisting of H, halogen, CN, NO_2, and SO_2R4

R3 is selected from the group consisting of C_{0-6} alkyl, and C_{0-6} alkenyl, optionally substituted;

R4 is selected from the group consisting of OH, OC_{1-7} alkyl, optionally substituted; NH_2, and NHR4

R5 is selected from the group consisting of aryl, fused aryl, dihydro, tetrahydro fused aryl, and heteroaryl, unsubstituted or substituted, with any substituent selected from the group consisting of OH, halogen, C_{1-4} alkyl, C_{1-4} alkoxy, CF_3, OCF_3, CN and NO_2.

2. A compound according to claim 1 selected from the group consisting of:

3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid;

3-{3,4-Difluoro-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid ethyl ester;

3-{3-Cyano-2-[(R)-2-hydroxy-3-(2-indan-2-yl-1, 1-dimethyl-ethyl amino)-propoxy]-phenyl}-propionic acid;

3-{3-Cyano-2-[(R)-2-hydroxy-3-(2-indan-2-yl-1, 1-dimethyl-ethyl amino)-propoxy]-phenyl}-propionic acid ethyl ester;

3-{3-Cyano-2-[(R)-2-hydroxy-3-(2-indan-2-yl-1, 1-dimethyl-ethyl amino)-propoxy]-phenyl}-pentanoic acid;

4-{3-Cyano-2-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-butyric acid; and
4-{3-Cyano-2-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-butyric acid ethyl ester.

3. A method of antagonizing a calcium receptor, which comprises administering to a subject in need thereof, an effective amount of a compound according to claim 1.

4. A method of treating a disease or disorder characterized by an abnormal bone or mineral homeostasis, which comprises administering to a subject in need of treatment thereof an effective amount of a compound of claim 1.

5. A method according to claim 4 wherein the bone or mineral disease or disorder is selected from the group consisting of osteosarcoma, periodontal disease, fracture healing, osteoarthritis, joint replacement, rheumatoid arthritis, Paget's disease, humoral hypercalcemia, malignancy and osteoporosis.

6. A method according to claim 5 wherein the bone or mineral disease or disorder is osteoporosis.

7. A method according to claim 6 wherein the compound is co-administered with an anti-resorptive agent.

8. A method according to claim 7 wherein the anti-resorptive agent is selected from the group consisting of estrogen, 1, 25 $(OH)_2$ vitamin D3, calcitonin, selective estrogen receptor modulators, vitronectin receptor antagonists, V-H+-ATPase inhibitors, src SH2 antagonists, bisphosphonates and cathepsin K inhibitors.

9. A method of increasing serum parathyroid levels which comprises administering to a subject in need of treatment an effective amount of a compound of claim 1.

10. A method according to claim 9 wherein the compound is co-administered with an anti-resorptive agent.

11. A method according to claim 10 wherein the anti-resorptive agent is selected from the group consisting of: estrogen, 1, 25 $(OH)_2$ vitamin D3, calcitonin, selective estrogen receptor modulators, vitronectin receptor antagonists, V-H+-ATPase inhibitors, src SH2 antagonists, bisphosphonates and cathepsin K inhibitors.